CENTER FOR SINGLE PHOTO-EMITTING CANCER IMAGING AGENTS:

单一光发射癌症成像剂中心：

• 批准号: 6377896
• 负责人: Wynn A Volkert
• 金额: $ 40万
• 依托单位: UNIVERSITY OF MISSOURI-COLUMBIA
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-04-14 至 2003-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6377896
• 关键词: SCID mouse; angiogenesis; bacterial virus; bioimaging /biomedical imaging; biomedical resource; breast neoplasms; chemical conjugate; colorectal neoplasms; dogs; imaging /visualization /scanning; indium; iodine; molecular oncology; prostate neoplasms; protooncogene; radionuclides; radiopharmacology; radiotracer; technetium; tissue inhibitor of metalloproteinases

The University of Missouri-Columbia (MU) is applying for a P-20 Pre-In vivo Cellular and Molecular Imaging (PRE-ICMIC) planning grant. The research projects that will be supported by this grant focus on the identification and development of single photon emitting site-directed in vivo targeting biomolecule- conjugates directed to cell surface receptor antigens and angiogenesis markers with high specificity. Molecular biological techniques form the primary approach for the design and generation of new cancer targeting vectors (incl., phage display, combinatorial chemistry and SPPS). The PRE-ICMIC will provide essential support to catalyze the formation of interdisciplinary research teams which are composed of scientists that combine expertise in molecular biology, chemistry, radiopharmaceutical chemistry, comparative oncology, pharmacology, tumor biology and pathology, and Nuclear Medicine. The research programs developed as part of this PRE-ICMIC are focussed on development of Tc-99m- and In-111-labeled diagnostic imaging agents. The organizational structure and Core facilities that will be instituted will support and promote cross-disciplinary research activities. This planning grant will be a critical milestone for establishment of a ICMIC at MU and will facilitate expansion and enhance the scope and quality of the radiopharmaceutical sciences research related to development of novel, highly specific cancer targeting imaging agents at this institution. At the completion of this grant, MU plans to be positioned to successfully apply for a P-50 ICMIC.

密苏里-哥伦比亚大学（MU）正在申请P-20预体内细胞和分子成像（PRE-ICMIC）规划补助金。 该基金支持的研究项目将集中于识别和开发单光子发射定点体内靶向生物分子-针对细胞表面受体抗原和高特异性血管生成标记物的缀合物。 分子生物学技术形成了设计和产生新的癌症靶向载体的主要方法（包括，噬菌体展示、组合化学和SPPS）。 PRE-ICMIC将提供必要的支持，以促进跨学科研究团队的形成，该团队由联合收割机结合分子生物学，化学，放射性药物化学，比较肿瘤学，药理学，肿瘤生物学和病理学以及核医学的专业知识的科学家组成。 作为PRE-ICMIC的一部分，开发的研究项目集中在Tc-99 m和In-111标记的诊断成像剂的开发上。 将建立的组织结构和核心设施将支持和促进跨学科的研究活动。 这项规划补助金将是在MU建立ICMIC的一个重要里程碑，并将促进扩大和提高放射性药物科学研究的范围和质量，这些研究与该机构开发新型，高度特异性的癌症靶向成像剂有关。 在这笔赠款完成后，MU计划成功申请P-50 ICMIC。